Safety and Usefulness of Intravenous Iron Sucrose in the Management of Preoperative Anemia in Patients with Menorrhagia: A Phase IV, Open-Label, Prospective, Randomized Study

2009 ◽  
Vol 121 (1) ◽  
pp. 37-41 ◽  
Author(s):  
Yun Hwan Kim ◽  
Hyun Hoon Chung ◽  
Soon-Beom Kang ◽  
Seung Cheol Kim ◽  
Young Tae Kim
Keyword(s):  
Randomized Study ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Prospective Randomized Study ◽  
Open Label ◽  
Preoperative Anemia ◽  
Phase Iv

Intravenous iron sucrose versus oral iron administration for the postoperative treatment of post-bariatric abdominoplasty anaemia: an open-label, randomised, superiority trial in Brazil

2018 ◽  
Vol 5 (7) ◽  
pp. e310-e320 ◽  
Author(s):  
Juan Carlos Montano-Pedroso ◽  
Elvio Bueno Garcia ◽  
Mariana Alcântara Rodrigues de Moraes ◽  
Daniela Francescato Veiga ◽  
Lydia Masako Ferreira
Keyword(s):  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Postoperative Treatment ◽  
Open Label ◽  
Iron Administration ◽  
Superiority Trial

scholarly journals Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery

2022 ◽  
Author(s):  
Michael Auerbach ◽  
Maureen M. Achebe ◽  
Lars L. Thomsen ◽  
Richard J. Derman
Keyword(s):  
Bariatric Surgery ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Efficacy And Safety ◽  
Open Label ◽  
Level Increase ◽  
Post Bariatric Surgery

Abstract Purpose Iron deficiency is common following bariatric surgery, and treatment with intravenous iron is often required. This post hoc analysis of data from two randomized, open-label, multicenter trials evaluated the efficacy and safety of ferric derisomaltose (FDI; formerly iron isomaltoside 1000) versus iron sucrose (IS) over 4 weeks in adults with iron deficiency anemia (IDA) resulting from prior bariatric surgery. Materials and methods Data were pooled for participants who received FDI or IS in the PROVIDE or FERWON-IDA trials for the treatment of IDA post bariatric surgery. Efficacy outcomes included changes in hemoglobin (Hb) and iron parameters; safety outcomes included the incidence of adverse drug reactions (ADRs), serious or severe hypersensitivity reactions (HSRs), and hypophosphatemia. Results The analysis included 159 patients. Mean (standard deviation) cumulative iron doses were 1199 (± 347) mg for FDI and 937 (± 209) mg for IS. Compared with IS, FDI resulted in a faster and more pronounced Hb response, and a higher proportion of responders (Hb level increase ≥ 2 g/dL from baseline) at all time points. The incidence of ADRs was similar with FDI and IS (15.1% and 18.2%, respectively), with no serious ADRs or serious or severe HSRs reported. The incidence of hypophosphatemia was low and similar in both treatment groups, with no cases of severe hypophosphatemia observed. Conclusions In patients with IDA resulting from bariatric surgery, FDI produced a faster and more pronounced Hb response than IS. Both FDI and IS were well tolerated. Graphical abstract

Sign in / Sign up

Export Citation Format

Share Document